1. 2630 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib trial. (September 2015) Authors: Apolo, A.B.; Infante, J.R.; Hamid, O.; Patel, M.; Wang, D.; Kelly, K.; Mega, A.; Britten, C.D.; Mita, A.; Ravaud, A.; Cuillerot, J.M.; Von Heydebreck, A.; Gulley, J.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S522 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity. (September 2015) Authors: Disis, M.L.; Patel, M.; Pant, S.; Hamilton, E.P.; Lockhart, A.C.; Kelly, K.; Thaddeus-Beck, J.; Gordon, M.; Weiss, G.J.; Ejadi, S.; Taylor, M.H.; Chin, K.; Cuillerot, J.M.; Von Heydebreck, A.; Gulley, J.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S546 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial. (September 2015) Authors: Hassan, R.; Thomas, A.; Patel, M.; Nemunaitis, J.; Bennouna, J.; Powderly, J.; Taylor, M.; Cuillerot, J.M.; Heydebreck, A. Von; Gulley, J.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S639 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗